Pfizer - C4201002

What is the Purpose of this Study?

If you choose to join this study, you will:
- Take the study drug (PF-07265807) by mouth
- Provide old tumor tissue
- Have physical exams, blood and urine tests
- Have eye exams
- Have imaging scans (CT and/or MRI)
- Have heart tests (ECG)


What is the Condition Being Studied?
Cancer that is locally advanced (cancer that has grown outside the organ it started in but has not yet spread to the distant part of your body) OR metastatic (cancer that has spread from the primary organ site into different areas of your body).

Who Can Participate in this Study?

Adults diagnosed with:

- Cervical cancer

- Gastric cancer

- Esophageal cancer

- Endometrial cancer

- HCC (Hepatocellular carcinoma)

- Melanoma (mucosal or cutaneous)

- Merkel cell carcinoma

- MSI-H tumors

- NSCLC (Non-small cell lung cancer)

- HNSCC (head and neck squamous cell cancer)

- SCLC (small cell lung cancer)

- RCC (renal cell carcinoma)

- Urothelial carcinoma

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to find out if an experimental drug, PF-07265807, is safe and to find the most effective dose.

Study Details

Full Title
A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF-07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANACIES
Principal Investigator

Protocol Number
IRB:
PRO00106013

NCT:
NCT04458259
ClinicalTrials.gov
View on ClinicalTrials.gov